Bone marrow angiogenesis in multiple myeloma
- PMID: 16357836
- DOI: 10.1038/sj.leu.2404067
Bone marrow angiogenesis in multiple myeloma
Abstract
Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and has prognostic potential. It is induced by plasma cells via angiogenic factors with the transition from monoclonal gammopathy of undetermined significance (MGUS) to MM, and probably with loss of angiostatic activity on the part of MGUS. The pathophysiology of MM-induced angiogenesis is complex and involves both direct production of angiogenic cytokines by plasma cells and their induction within the microenvironment. The latter are secreted by stromal cells, endothelial cells (EC) and osteoclasts, and promote plasma cell growth, survival and migration, as well as paracrine cytokine secretion and angiogenesis in the bone marrow milieu. Angiogenesis is also supported by inflammatory cells following their recruitment and activation by plasma cells. Finally, circulating EC and endothelial precursor cells (EPC) contribute to the neovascularization, and the presence of EPC suggests that vasculogenesis (new vessel formation from EPC) may also contribute to the full MM vascular tree.
Similar articles
-
Angiogenesis in multiple myeloma.Eur J Cancer. 2006 Jul;42(11):1581-90. doi: 10.1016/j.ejca.2006.02.017. Epub 2006 Jun 23. Eur J Cancer. 2006. PMID: 16797965 Review.
-
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.Clin Cancer Res. 2002 Jul;8(7):2210-6. Clin Cancer Res. 2002. PMID: 12114422
-
Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.Blood. 1999 May 1;93(9):3064-73. Blood. 1999. PMID: 10216103
-
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.Blood. 2004 Aug 15;104(4):1159-65. doi: 10.1182/blood-2003-11-3811. Epub 2004 May 6. Blood. 2004. PMID: 15130943
-
Angiogenesis in multiple myeloma.Chem Immunol Allergy. 2014;99:180-96. doi: 10.1159/000353312. Epub 2013 Oct 17. Chem Immunol Allergy. 2014. PMID: 24217610 Review.
Cited by
-
The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis.Cancers (Basel). 2020 Aug 19;12(9):2341. doi: 10.3390/cancers12092341. Cancers (Basel). 2020. PMID: 32825035 Free PMC article.
-
Extravasation and homing mechanisms in multiple myeloma.Clin Exp Metastasis. 2008;25(4):325-34. doi: 10.1007/s10585-007-9108-4. Epub 2007 Oct 19. Clin Exp Metastasis. 2008. PMID: 17952614 Review.
-
Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives.Front Med. 2012 Mar;6(1):67-78. doi: 10.1007/s11684-012-0176-8. Epub 2012 Mar 31. Front Med. 2012. PMID: 22460450 Review.
-
Increased serum levels of MIP-1alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma.Med Oncol. 2014 Jan;31(1):778. doi: 10.1007/s12032-013-0778-2. Epub 2013 Nov 26. Med Oncol. 2014. PMID: 24277416
-
Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.Blood. 2008 Aug 1;112(3):750-9. doi: 10.1182/blood-2008-02-139378. Epub 2008 May 12. Blood. 2008. PMID: 18474725 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical